Varoglutamstat is under clinical development by Vivoryon Therapeutics and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Varoglutamstat’s likelihood of approval (LoA) and phase transition for Alzheimer’s Disease took place on 23 Dec 2021, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Varoglutamstat Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Varoglutamstat overview

PQ-912 is under development for the treatment of early stage mild dementia due to Alzheimer’s disease (AD), mild cognitive impairment, cancer and Huntington disease. It is administered orally. The drug candidate acts by targeting glutaminyl cyclase (QC).

Vivoryon Therapeutics overview

Vivoryon Therapeutics N.V. (Vivoryon), formerly known as Vivoryon Therapeutics AG, is a biopharmaceutical company that conducts clinical-stage research and development of new medicines for the treatment of alzheimer’s disease. The company offers three pipeline drug candidates such as PQ912, PBD-C06 and PQ1565. Its PQ912 drug candidate is a small molecule glutaminyl cyclase inhibitor that inhibits QC-enzyme for animal models. Vivoryon’s PBD-C06 is a monoclonal antibody under evaluation which clear toxic pyroglutamate-Abeta in the brain. The company’s PQ1565 is a second QC inhibitor in preclinical stage and demonstrated attractive drug-like properties. It also develops a therapeutic approach, dipeptidyl peptidase 4 inhibitors for the treatment of diabetes. Vivoryon is headquartered in Halle, Germany.

Quick View Varoglutamstat LOA Data

Report Segments
  • Innovator
Drug Name
  • Varoglutamstat
Administration Pathway
  • Oral
Therapeutic Areas
  • Central Nervous System
  • Oncology
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.